“Use With Caution” Isn’t Specific Enough For Labeling, FDA Tells Merck At Vorapaxar Panel
Advisory committee struggles to give a labeling recommendation for lightweight patients, who saw lower efficacy using the platelet inhibitor.
You may also be interested in...
Novel antiplatelet product has suffered from excess bleeding rates in clinical trials and is searching for an appropriate patient population, after initial hopes of being a blockbuster.
Senate appropriations bill would take back some of increase House offered Center for Drug Evaluation and Research and other FDA programs, setting up negotiations as start of FY2023 nears.
Furloughs would allow affected FDA staff to remain employed, while a layoffs would require affected workers to be rehired.